Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 101.09
(-0.7%)
CNY 101.09
(-0.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -408.79 Million CNY | 18.86% |
| 2022 | -503.82 Million CNY | -0.24% |
| 2021 | -502.63 Million CNY | -40.39% |
| 2020 | -358.03 Million CNY | 18.59% |
| 2019 | -439.78 Million CNY | 0.65% |
| 2018 | -442.64 Million CNY | -202.22% |
| 2017 | -146.46 Million CNY | -9.6% |
| 2016 | -133.63 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -58.22 Million CNY | 58.0% |
| 2024 Q2 | -49.96 Million CNY | 14.19% |
| 2024 Q3 | -33.11 Million CNY | 33.73% |
| 2023 Q4 | -138.62 Million CNY | -47.15% |
| 2023 FY | -408.79 Million CNY | 18.86% |
| 2023 Q3 | -94.2 Million CNY | -52.45% |
| 2023 Q2 | -61.79 Million CNY | -2.36% |
| 2023 Q1 | -60.36 Million CNY | 37.91% |
| 2022 FY | -503.82 Million CNY | -0.24% |
| 2022 Q3 | -126.97 Million CNY | 9.5% |
| 2022 Q2 | -140.3 Million CNY | -3.06% |
| 2022 Q1 | -136.14 Million CNY | 10.94% |
| 2022 Q4 | -97.22 Million CNY | 23.43% |
| 2021 Q2 | -103.45 Million CNY | -23.22% |
| 2021 Q1 | -83.95 Million CNY | 16.96% |
| 2021 FY | -502.63 Million CNY | -40.39% |
| 2021 Q4 | -152.86 Million CNY | -28.7% |
| 2021 Q3 | -118.77 Million CNY | -14.81% |
| 2020 Q4 | -101.1 Million CNY | -51.57% |
| 2020 Q3 | -66.7 Million CNY | 5.44% |
| 2020 Q1 | -66.47 Million CNY | 4.51% |
| 2020 FY | -358.03 Million CNY | 18.59% |
| 2020 Q2 | -70.54 Million CNY | -6.11% |
| 2019 FY | -439.78 Million CNY | 0.65% |
| 2019 Q4 | -69.62 Million CNY | -14.39% |
| 2019 Q3 | -60.86 Million CNY | 55.13% |
| 2019 Q2 | -135.64 Million CNY | 21.89% |
| 2019 Q1 | -173.66 Million CNY | 50.53% |
| 2018 Q4 | -351.01 Million CNY | 0.0% |
| 2018 FY | -442.64 Million CNY | -202.22% |
| 2017 FY | -146.46 Million CNY | -9.6% |
| 2016 FY | -133.63 Million CNY | 0.0% |